Shuren Touts Pre-Market Benefits Of Planned National Post-Market Strategy
This article was originally published in The Gray Sheet
Executive Summary
CDRH is drafting a national comprehensive post-market strategy, due out this spring. While a principle goal is catching safety problems earlier, Jeffrey Shuren hopes the plan will ultimately make data collection less burdensome for industry, both in the pre-market and post-market stages.
You may also be interested in...
Industry Urges Caution In Response To Growing Push For 'Real-World' Device Evaluation System
AdvaMed's new chief Scott Whitaker says industry doesn't want to sign onto a new "national evaluation system" for devices championed by FDA until it is convinced that the initiative will enhance, rather than hinder, premarket product development.
Regulatory News In Brief
FDA plans the imminent release of a white paper outlining a new national medical device post-market surveillance strategy in the lead up to public meetings Sept.10-13. More regulatory news below.
FDA’s UDI Draft Rule Details Device Marking, Database Submission Mandates
The long-anticipated proposal maps out a unique device identifier system that FDA says will be crucial to the future of post-market safety surveillance, recall management and safety alerts. The effort also will help reduce medical errors and bring an array of other benefits, stakeholders say.